Now showing summary data for the 2024 election cycle. Now showing data for the election cycle. Pharmaceutical companies, which develop both over-the-counter and prescription drugs, have been among the ...

Now showing summary data for the 2024 election cycle. Now showing data for the election cycle. The pharmaceutical and health products industry — including not only drug manufacturers but also dealers ...

The Trump campaign says discussions of who might serve in key Cabinet roles are “premature,” but that hasn’t stopped D.C.’s ...

The UMass Lowell graduate certificate program is a four-course program in Pharmaceutical Sciences intended for individuals with diverse backgrounds who are interested in getting familiar with ...

Fintel reports that on September 19, 2024, B. Riley Securities initiated coverage of Centessa Pharmaceuticals plc - ...

Biomarin Pharmaceutical Background Information (This description is provided by the company.) BioMarin is a global biotechnology company that develops and commercializes innovative therapies for ...

Amphastar Pharmaceuticals offers growth potential with diverse products, a solid balance sheet, and manageable risks. Find ...

Braidwell holds 2,058K shares representing 5.07% ownership of the company. No change in the last quarter. Kiniksa ...

Secondary metabolites promise an increasing value for the treatment of metabolic disorders and infectious diseases. With the progress achieved in molecular biology and metabolomic studies, those ...

In terms of the Debt-to-Equity ratio, Regeneron Pharmaceuticals can be assessed by comparing it to its top 4 peers, resulting in the following observations: Regeneron Pharmaceuticals demonstrates ...

In July, the Senate Armed Services Committee passed its version of the FY 2025 National Defense Authorization Act (NDAA), ...

In terms of the Debt-to-Equity ratio, Regeneron Pharmaceuticals can be assessed by comparing it to its top 4 peers, resulting in the following observations: In terms of the debt-to-equity ratio ...